Cited by 73Diabetes Management and ResearchDiabetes and associated disordersDiabetes Treatment and Management

Diabetic ketoacidosis: A common debut of diabetes among African Americans with type 2 diabetes

Open access
Vellanki, Priyathama, Umpierrez, Guillermo E.·2017·Endocrine Practice

Abstract

Objective More than half of African Americans (AA) with a new diagnosis of diabetic ketoacidosis have clinical and metabolic features of type 2 diabetes during follow-up. This particular presentation of diabetes has been termed as ketosis-prone type 2 diabetes (KPDM) or atypical diabetes.Methods We review the epidemiology, diagnosis, pathophysiology, and acute and long-term management of AA with KPDM and compare these similarities to patients with type 2 diabetes.Results In contrast to the long-term insulin requirement of auto-immune type 1 diabetes, patients with KPDM are able to discontinue insulin after a few months of therapy and maintain acceptable glycemic control for many years on either diet or oral agents. Patients with KPDM have significant impairment of both insulin secretion and insulin action at presentation; however, at the time of near-normoglycemia remission, insulin secretion and action improve to levels similar to hyperglycemic patients with ketosis-resistant type 2 diabetes. In the long term, however, patients with KPDM have a decline in β-cell function similar to patients with type 2 diabetes. Recent studies indicate that treatment with metformin and dipeptidyl peptidase-4 inhibitors can prolong the period of near-normoglycemia remission for several years compared to placebo therapy.Conclusion KPDM is a unique but common presentation of newly diagnosed African Americans with type 2 diabetes.Abbreviations A(+/-) = auto-antibody positive/negative AA = African Americans DKA = diabetic ketoacidosis FFA = free fatty acids G6PD = glucose-6-phosphate dehydrogenase GAD-65 = 65-kDA glutamic acid decarboxylase HBA1c = glycated hemoglobin A1c HHV8 = human herpes virus 8 HLA = human leukocyte antigen KPDM = ketosis-prone type 2 diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4158/ep161679.ra

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [44]44. Boutin P, Gresh L, Cisse A, et al. Missense mutation Gly574Ser in the transcription factor HNF-1alpha is a marker of atypical diabetes mellitus in African-American children. Diabetologia. 1999; 42:380-381. [PubMed: 10096793]

Cited by

Sorted by citations

Authors
Vellanki, P., & Umpierrez, G. E.
Affiliations
Emory University (US)
Corresponding author
Umpierrez, Guillermo E.
Venue
Endocrine Practice
Publisher
Elsevier BV
Published
2017-08
Volume
23
Issue
8
Pages
971-978
ISSN
1530-891X (ISSN-L)
OpenAlex
W2618920464
Cited by
73
References
50
Citations by year
2026: 4 · 2025: 7 · 2024: 9 · 2023: 13 · 2022: 11 · 2021: 8 · 2020: 8 · 2019: 6 · 2018: 6 · 2017: 1
FWCI
0.84
Type
journal article
Language
en
Open access
Locations
  • Endocrine Practice (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • American Diabetes Association (1-14-LLY-36)
  • AstraZeneca
  • Sanofi
  • Emory University (RR025008)
  • Novo Nordisk
  • National Institutes of Health (RR025008)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK111024)
  • National Center for Research Resources (UL1RR025008, RR025008)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
diabetic ketoacidosis, ketosis-prone type 2 diabetes, African Americans, type 2 diabetes, insulin secretion, insulin resistance, beta-cell function, remission, metformin, DPP-4 inhibitors, insulin discontinuation, pathophysiology
MeSH terms
Black or African American, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Diabetic Ketoacidosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review